ANIP FY 2018 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

FY 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$202M+14.0% YoY

Gross Profit

$129M63.8% margin

Operating Income

$35M17.5% margin

Net Income

$15M7.7% margin

EPS (Diluted)

$1.32

Cash Flow

Operating Cash Flow

$67M

Free Cash Flow

$56M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$431M

Total Liabilities

$233M

Stockholders' Equity

$197M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$202M	$177M	+14.0%
Gross Profit	$129M	$98M	+31.4%
Operating Income	$35M	$28M	+24.8%
Net Income	$15M	-$1M	+1540.0%